Lead by proven industry experience, Marvel is at the forefront of modern science.
Marvel Biosciences is an agile Calgary-based biotechnology company revolutionizing drug development by de-risking the (re)development of existing drugs to create novel therapeutics with enhanced efficacy and safety profiles. We capitalize on modifying known, off-patent drugs to deliver faster, safer, and more effective treatments. Our streamlined approach significantly reduces development costs, shortens timelines, and lowers risk compared to traditional biotech models.
Our lead compound has shown remarkable promise in preclinical studies, demonstrating efficacy for a wide range of conditions, including Alzheimer’s Disease, Depression, Anxiety, and Autism. We are also actively investigating its potential in addressing other neurodevelopmental genetic disorders, such as Rett Syndrome and Fragile X Syndrome, to further expand our therapeutic reach. We have completed cGMP synthesis, toxicology studies, and preparation for Phase 1 clinical trials and are well-positioned to bring our groundbreaking solutions to market.
Marvel Biosciences is a company poised to transform the treatment landscape for multiple high-need indications, tapping into markets with multi-billion dollar potential and minimal competition. Our focus on the A2A adenosine receptor – a target with significant therapeutic promise – sets us apart in our mission to address unmet medical needs.
Our drug assets are strategically developed to target large and growing markets, addressing significant unmet medical needs across diverse patient populations.
Marvel Biosciences is specifically targeting
Neurological Diseases
Developing treatments for conditions such as Alzheimer’s Disease, where effective therapeutic options remain limited.
Cognitive and Behavioral Health
Addressing mental health conditions like depression and anxiety to improve patients’ quality of life.
Neurodevelopmental and Genetic Disorders
Targeting Autism, Rett Syndrome, and Fragile X Syndrome, to enhance outcomes for patients and families affecting by these challenging conditions.
Stock Information
Shares Outstanding : 39,786,231
Insider Ownership : 13,575,098 (34.1%)
Stock options granted : 3,350,000
Recent News
Marvel Biosciences Shares Positive Results of MB204 in the Oprm1 Model of Autism
Calgary, Alberta – October 10, 2024 – Marvel Biosciences Corp. (TSXV: MRVL OTC: MBCOF), and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the “Company” or “Marvel”), today shared promising results from a recent study on MB204. The research was...
Marvel Announces Its Collaboration with FRAXA to Test MB204 In Pre-Clinical Models of Fragile X Syndrome
Calgary, Alberta – August 13, 2024 – Marvel Biosciences Corp. (TSXV: MRVL OTC: MBCOF), and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the “Company” or “Marvel”), is pleased to announce it has entered a collaboration with the FRAXA Research...
Contact
Marvel Biosciences Corp.
Suite 420, 505 8th Avenue S.W.
Calgary, Alberta T2P 1G2
(403) 770-2469
Marvel Biosciences
Marvel Biosciences Corp. (the “Company”) is a life sciences company whose primary focus is the discovery and the development of a synthetic derivative compound of a known proven drug.